Pancreatic Cancer Detection Consortium
NCT06388967
This study is recruiting at 9 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Cancer
- Pancreatic Carcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Neoplasms
- Pancreatic Cancer Stage I
- Pancreatic Cancer Stage
- Pancreatic Cancer Resectable
- Pancreatic Cancer Stage 0
- Pancreatic Cancer Stage II
- Pancreatic Cancer Stage III
- Pancreatic Cancer, Adult
- Pancreatic Cancer Non-resectable
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- City of Hope Medical Center
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Translational Genomics Research Institute · Phoenix, AZ
California · 1
- City of Hope Medical Center · Monrovia, CA
Illinois · 1
- OSF HealthCare · Peoria, IL
Louisiana · 1
- Ochsner Medical Center · Jefferson, LA
New Jersey · 1
- Atlantic Health System · Morristown, NJ
Pennsylvania · 1
- AHN Cancer Institute at Allegheny General Hospital · Pittsburgh, PA
South Carolina · 1
- Piedmont Medical Center · Rock Hill, SC
Washington · 1
- MultiCare Cancer Institute - Tacoma General Hospital · Tacoma, WA
Wisconsin · 1
- Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.